Company Profile
Immutep Limited Stock Price, News & Analysis
- Ticker:
- IMMP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
0.38 USD (-4.36%)
Close
Last updated: August 6, 2026
61.3M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IMMP closed down 4.36% at $0.3751. No new same-company headline was identified in the current news window.
Company overview
Business overview
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
Geographic Base and Sector Classification
Immutep is headquartered in Australia and listed in the U.S. market. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical readouts, translational validation, and the ability to maintain a narrow immunotherapy pipeline. Investors usually watch efficacy signals and strategic collaborations.
Position Within the Biotechnology Landscape
Immutep occupies a specialized immuno-oncology niche within biotech. The stock is catalyst-sensitive because the platform still needs to prove broad clinical relevance.
Future catalysts
Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.
Recent news
- 01
Immutep Quarterly Activities Report Q4 FY26
Source: Immutep Limited
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Immutep Limited (IMMP)?
Immutep Limited (IMMP) most recently closed at 0.38 USD, a -4.36% move versus the previous session.
What is the market cap of Immutep Limited (IMMP)?
Immutep Limited currently has a market capitalization of 61.3M USD on BioPharmSignal.
What does Immutep Limited do?
Immutep is a biotechnology company focused on immunotherapy and checkpoint modulation, with programs in cancer and immune disease. Its story is built around developing differentiated immune therapies that can complement existing oncology treatments.
On which exchange is IMMP stock listed?
Immutep Limited (IMMP) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is Immutep?
Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment.
Which conditions is Immutep Limited targeting with Immutep?
Immutep Limited is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Immutep Limited describe recent progress with Immutep?
Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment.
What future catalysts are investors watching for Immutep Limited?
Immutep’s catalysts are eftilagimod alfa and the immuno-oncology program, where the next update can significantly shift sentiment. The company still needs human proof.